Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cyproterone→

Cyproterone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2098-66-0
Molecular formula
C22H27ClO3
Molecular weight
374.9 g/mol
Drug class
Steroidal antiandrogen with progestational activity (catalogue name commonly refers to cyproterone acetate)
Mechanism of action
Cyproterone acetate binds androgen receptors and blocks androgen-mediated receptor activation. Its progestational action at the pituitary reduces luteinising-hormone secretion and can lower testicular androgen production; suppression is not complete when used alone.
Indications / reported uses
  • Management of prostate cancer in the specific cyproterone-acetate 50 mg product information; other strengths and combinations have different indications and risk profiles

Sources: UK SmPC — Cyprostat (cyproterone acetate) · NCI Drug Dictionary

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cyproterone Environmental Risk Assessment (ERA) (the Cyproterone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.